Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCK | P08631 | 9/20 | 0.49 |
| ▸ | BTK | Q06187 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 6/20 | 0.49 |
| ▸ | BCR | P11274 | 5/20 | 0.48 |
| ▸ | LCK | P06239 | 9/20 | 0.46 |
| ▸ | LYN | P07948 | 8/20 | 0.46 |
| ▸ | SRC | P12931 | 8/20 | 0.46 |
| ▸ | KDR | P35968 | 8/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.46 |
| ▸ | INSR | P06213 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20925396 | 0.86 | ABL1 (0.55) | HCKBTKABL1BCR | |
| SCHEMBL13820441 | 0.84 | HCK (0.51) | HCKBTKABL1BCRKDR | |
| SCHEMBL3397844 | 0.82 | BRAF (0.55) | HCKABL1BCRLYNSRC | |
| SCHEMBL16373769 | 0.82 | BRAF (0.48) | HCKABL1BCRSRC | |
| SCHEMBL3232951 | 0.82 | LCK (0.56) | HCKBTKABL1BCRLCK | |
| SCHEMBL13292048 | 0.81 | LCK (0.58) | HCKLCKLYNSRCKDR | |
| SCHEMBL3240152 | 0.81 | LCK (0.56) | HCKABL1BCRLCKLYN | |
| SCHEMBL1824307 | 0.80 | LCK (0.59) | HCKLCKLYNSRCKDR | |
| SCHEMBL3236253 | 0.80 | POLB (0.61) | HCKLCKLYNSRCKDR | |
| SCHEMBL1822079 | 0.80 | LCK (0.56) | HCKBTKLCKLYNSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-05-16 | — | — | US | claimed |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | claimed |
| US-20170349595-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-12-07 | — | — | US | claimed |
| EP-2222162-B1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2016-11-16 | — | — | EP | claimed |
| US-20150094275-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-04-02 | — | — | US | claimed |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2011-12-22 | — | — | US | claimed |
| EP-2222162-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana Farber Cancer Institute (US) | 2010-09-01 | — | — | EP | claimed |
| WO-2009073153-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INSTITUTE (US) | 2009-06-11 | — | — | WO | claimed |
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-22 | — | — | US | disclosed |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2011-12-22 | — | — | US | disclosed |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2011-12-22 | — | — | US | disclosed |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2011-12-22 | — | — | US | disclosed |
| EP-2222162-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana Farber Cancer Institute (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009073153-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INSTITUTE (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009073153-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INSTITUTE (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | BCR, ABL1, MCL1 | HCK 1047/4885BTK 27/4885ABL1 2/4885 |
| US-20150094275-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | HCK 350/4885BTK 17/4885ABL1 2/4885 |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | HCK 1123/4885BTK 24/4885ABL1 2/4885 |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | BCR, ABL1, MCL1 | HCK 1123/4885BTK 24/4885ABL1 2/4885 |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | HCK 596/4885BTK 45/4885ABL1 2/4885 |
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | HCK 1295/4885BTK 17/4885ABL1 2/4885 |
| US-20170349595-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND ABL AND METHODS OF USE | BCR, ABL1, ABL2 | HCK 635/4885BTK 19/4885ABL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.